_the-benefits-of-177lu-psma-617-plus-olaparib-for-prostate-cancer-preview-1.jpg "The benefits of 177Lu-PSMA-617 plus olaparib for prostate cancer from olaparib prostate cancer Video Screenshot Preview 1")
Gallery_the-benefits-of-177lu-psma-617-plus-olaparib-for-prostate-cancer-preview-3.jpg "The benefits of 177Lu-PSMA-617 plus olaparib for prostate cancer from olaparib prostate cancer Video Screenshot Preview 3")
Gallery_the-benefits-of-177lu-psma-617-plus-olaparib-for-prostate-cancer-preview-hqdefault.jpg "The benefits of 177Lu-PSMA-617 plus olaparib for prostate cancer from olaparib prostate cancer Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 1 minute 6 seconds
👁 View: 71 times
Play Audio:👁 View: 71 times
Description:
VJOncology
VJOncology
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_fatima-karzai-md-on-prostate-cancer-treatment-study-results.webp "Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).")
_dr-morgan-on-olaparib-for-metastatic-castration-resistant-prostate-cancer.webp "OncLiveTV")
⏲ 1 minute 38 seconds 👁 466
_olaparib-zytiga-for-metastatic-castrate-resistant-prostate-cancer-124-learn-about-clinical-trials.webp "Prostate Cancer Research Institute")
⏲ 3 minutes 48 seconds 👁 2.1K
_highlights-from-asco-2019.webp "Assistant Prof Bishal Gyawali and Monique Biryiana speak at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the highlights from this year's conference. nnAssistant Prof Gyawali discusses several presentations that address topics ranging from racial disparities, accelerated drug approvals and the importance of assessing overall survival in clinical trials. nnThe presentations that he refer to are: nnAffordable Care Act (ACA) Medicaid expansion impact on racial dispariti")
_olaparib-and-keytruda-for-advanced-prostate-cancer-124-124-learn-about-clinical-trials.webp "Prostate Cancer Research Institute")
⏲ 5 minutes 14 seconds 👁 1.6K
_asco-2023-highlights-and-analysis.webp "Associate Prof Bishal Gyawali discusses several presentations that on topics ranging from adjuvant treatments, neo-adjuvant treatments and supportive care, across a range of cancer types. He concludes by giving his opinion on issues with drug approval. nnThe presentations referred to are:nn1.Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)n2.Phase III NATALEE trial of riboci")
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.webp "Vall d'Hebron Institute of Oncology - VHIO")
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.webp "VJOncology")
_fatima-karzai-md-on-prostate-cancer-treatment-study-results.jpg)
_dr-morgan-on-olaparib-for-metastatic-castration-resistant-prostate-cancer.jpg)
_olaparib-zytiga-for-metastatic-castrate-resistant-prostate-cancer-124-learn-about-clinical-trials.jpg)
_highlights-from-asco-2019.jpg)
_olaparib-and-keytruda-for-advanced-prostate-cancer-124-124-learn-about-clinical-trials.jpg)
_asco-2023-highlights-and-analysis.jpg)
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.jpg)
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.jpg)
![[+]](/images/menu.gif){kind=small}